WO2018021326A1 - 口腔粘膜貼付材及びその製造方法 - Google Patents
口腔粘膜貼付材及びその製造方法 Download PDFInfo
- Publication number
- WO2018021326A1 WO2018021326A1 PCT/JP2017/026898 JP2017026898W WO2018021326A1 WO 2018021326 A1 WO2018021326 A1 WO 2018021326A1 JP 2017026898 W JP2017026898 W JP 2017026898W WO 2018021326 A1 WO2018021326 A1 WO 2018021326A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral mucosa
- hyaluronic acid
- oral
- mucosa patch
- patch
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
Definitions
- the present invention relates to an oral mucosa patch and a method for producing the same.
- oral mucosa a type of mucosa covered with a type of mucosa called the oral mucosa, except for the teeth.
- stomatitis As oral mucosal diseases, aphthous stomatitis (so-called stomatitis), catarrhal stomatitis, ulcerative stomatitis, etc. in which symptoms are widely observed even in healthy subjects are known.
- aphthous stomatitis creates a grayish white spot with a diameter of several millimeters in the oral mucosa, and is accompanied by pain. Ingestion may cause severe pain due to food irritation, and in severe cases it may be impossible to eat.
- oral mucositis is said to have the highest frequency among side effects occurring in the mouth of patients receiving anticancer drug treatment and radiation therapy.
- anticancer drug treatment may cause symptoms such as inflammation of the mucous membrane inside the cheeks and lips and peeling of the mucous membrane. If the symptoms become severe, pain and other factors may make it difficult to eat from the mouth, and it may be necessary to discontinue treatment with anticancer drugs.
- tablets are poor in flexibility, they move softly on the tongue and under the tongue, and are not suitable for use in a wide range of sites.
- the powder preparation requires a dedicated jig for application on the mucous membrane and is not easy to use.
- the present invention has good handleability and has excellent sticking property that sticks to the oral mucosa even when there is a lot of moisture and saliva on the oral mucosal surface.
- the main object is to provide a novel oral mucosal patch that has the property of enhancing the effect of physically protecting the applied site by showing and the property of remaining at the applied site for a long time.
- the present inventor has intensively studied to solve the above problems.
- the polymer content in the lyophilized body is 20% by mass or more, and the hyaluronic acid in the polymer With a content of 50% by mass or more, the handleability is good, and even if there is a lot of moisture and saliva on the oral mucosa surface, it has excellent sticking properties that stick to the oral mucosa.
- an oral mucosa patch can be obtained that has the property of enhancing the effect of physically protecting the applied site by including elasticity and further having the property of remaining at the applied site for a long time.
- the present invention has been completed by further studies based on such findings.
- this invention provides the invention of the aspect hung up below.
- Item 1 An oral mucosa patch having a freeze-dried polymer-containing material on the adhesive surface with the oral mucosa, The content of the polymer in the lyophilized body is 20% by mass or more, An oral mucosal patch, wherein the hyaluronic acid content in the polymer is 50% by mass or more.
- Item 2. The oral mucosa patch according to Item 1, wherein the hyaluronic acid has a molecular weight of 1 ⁇ 10 5 daltons or more.
- Item 3. Item 3.
- Measurement method of intrinsic viscosity Weigh 50 mg of hyaluronic acid, dissolve in 0.2 mol / L sodium chloride solution to make 100 mL, and measure 10 mL, 15 mL, and 20 mL of this solution, add 0.2 mol / L sodium chloride solution to each, and add 25 mL. Each solution is used as a sample solution. Viscosity measurement of each sample solution and 0.2 mol / L sodium chloride solution in accordance with the provisions of “General Test Method 2.53 Viscosity Measurement Method 1.
- Item 7. Item 7.
- Item 8. Item 8.
- Item 10. Item 10.
- Item 11. Item 9. The oral mucosa patch according to any one of Items 1 to 8, which is used for desensitization therapy applied to the oral mucosa.
- Item 12. Item 9. The oral mucosa patch according to any one of Items 1 to 8, which is used for an oral cavity mucosal absorption preparation applied to the oral mucosa.
- Item 13 Item 13.
- the handleability is good, and even when there is a lot of moisture and saliva on the oral mucosal surface, it has excellent sticking properties to stick to the oral mucosa, and after application, it contains water and saliva and exhibits elasticity. It is possible to provide an oral mucosal patch that has the property of enhancing the effect of physically protecting the applied site, and further has the property of remaining at the applied site for a long time. Since the oral mucosa patch of the present invention exhibits such excellent effects, it can be suitably used for prevention or treatment of oral mucosal diseases. Similarly, the oral mucosa patch of the present invention can also be suitably used for desensitization therapy applied to the oral mucosa and oral cavity mucosa absorption preparations. Furthermore, according to this invention, the suitable manufacturing method of the said oral mucosa patch can be provided.
- the oral mucosa patch of the present invention is an oral mucosa patch having an lyophilized product containing a polymer on the adhesive surface with the oral mucosa, and the content of the polymer in the lyophilized product is 20% by mass or more. And the content of hyaluronic acid in the polymer is 50% by mass or more.
- the oral mucosa patch of the present invention has such a structure, so that it is easy to handle and has excellent adhesive properties to stick to the oral mucosa even when there is a lot of moisture and saliva on the oral mucosa surface. By exhibiting elasticity including moisture and saliva after sticking, it is possible to exhibit characteristics that enhance the effect of physically protecting the sticking site, and characteristics that remain at the sticking site for a long time.
- the oral mucosa of a patient suffering from an oral mucosal disease can be suitably protected for a long period of time, and pain associated with, for example, eating and drinking can be reduced.
- the oral mucosa patch and the method for producing the same will be described in detail.
- the oral mucosa patch of the present invention comprises a freeze-dried product containing a polymer on the adhesive surface with the oral mucosa. That is, in the oral mucosa patch of the present invention, the freeze-dried body serves as an adhesive surface with the oral mucosa and is used by being stuck to the surface of the oral mucosa.
- the oral mucosa means portions other than the teeth in the oral cavity, such as the inner cheek, upper jaw, tongue, sublingual, gums.
- the freeze-dried product containing a polymer can be obtained by freeze-drying an aqueous solution containing a polymer, for example.
- the freeze-dried body has a form such as cotton and sponge, and the water content is usually 5% by mass or less.
- the content of the polymer contained in the freeze-dried product is 20% by mass or more. Furthermore, the content of hyaluronic acid contained in the polymer is 50% by mass or more.
- the adhesive surface with the oral mucosa is composed of such a lyophilized body, the handleability is good, and even when there is a lot of moisture and saliva on the oral mucosa surface, It has excellent sticking properties to stick, and has the property of enhancing the effect of physically protecting the sticking site by showing moisture and saliva after sticking, and the property of remaining at the sticking site for a long time It becomes possible.
- the oral mucosa patch when the oral mucosa patch is applied to the oral cavity, the oral mucosa patch has a sufficient shape retaining property and is difficult to adhere to the hand, etc., so that it is excellent in handleability.
- the oral mucosa adhesive material when the oral mucosa adhesive material is attached to the oral mucosa, the freeze-dried body of the oral mucosa adhesive material instantaneously absorbs moisture and saliva on the oral mucosa surface and adheres to the oral mucosa.
- a good elastic gel-like material containing water and saliva is formed to physically protect the applied site.
- the oral mucosal patch of the present invention has an excellent sticking property to stick to the oral mucosa even when there is a lot of moisture and saliva on the surface of the oral mucosa.
- part for a long time are exhibited suitably.
- hyaluronic acid is used in a concept including hyaluronic acid and a salt thereof. Therefore, “hyaluronic acid and a salt thereof” may be simply referred to as “hyaluronic acid”.
- the salt of hyaluronic acid is not particularly limited, and examples thereof include sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate and the like.
- hyaluronic acid and its salt may be used individually by 1 type, and may be used in combination of 2 or more type.
- the average molecular weight of hyaluronic acid is not particularly limited, but it improves the handleability of the oral mucosa patch and has excellent adhesiveness that sticks to the oral mucosa even when there is a lot of moisture and saliva on the oral mucosa surface. From the viewpoint of suitably exhibiting the property of enhancing the effect of physically protecting the applied part by showing elasticity including saliva and saliva, and preferably remaining for a long time on the applied part, preferably 1 ⁇ 10 5 daltons The above is mentioned. More preferably, about 3.5 ⁇ 10 5 to 5 ⁇ 10 6 daltons, more preferably about 3.5 ⁇ 10 5 to 3 ⁇ 10 6 daltons, and even more preferably about 6 ⁇ 10 5 to 2.3 ⁇ 10 6 daltons. Particularly preferred is about 1.2 ⁇ 10 6 to 2.3 ⁇ 10 6 daltons. As the hyaluronic acid, one having a single molecular weight may be used, or plural kinds of molecular weights may be mixed and used.
- the intrinsic viscosity of hyaluronic acid measured by the following measurement method is not particularly limited, but preferably 3 (dL / g) or more. More preferably, it is about 8 to 55 (dL / g), more preferably about 8 to 40 (dL / g), still more preferably about 10 to 40 (dL / g), and particularly preferably 15 to 40 (dL / g). ) Degree.
- the hyaluronic acid one having a single molecular weight may be used, or plural kinds of molecular weights may be mixed and used.
- the specific viscosity is measured by the method in an environment of 30.0 ⁇ 0.1 ° C., and the reduced viscosity is calculated.
- a graph is drawn with the reduced viscosity on the vertical axis and the concentration of hyaluronic acid (g / 100 mL) on the horizontal axis, and the intrinsic viscosity is determined from the intersection of the straight line connecting the points and the vertical axis.
- the hyaluronic acid used as a raw material usually contains about several percent of water, but the “hyaluronic acid concentration” in the above formula means a concentration converted to dry hyaluronic acid. .
- the specific viscosity and the reduced viscosity are obtained from the following equations.
- hyaluronic acid is not particularly limited, and, for example, those isolated and extracted from chicken crowns, umbilical cords, etc., and those prepared by fermentation using microorganisms such as Streptococcus can be preferably used.
- a commercially available product can be used as the hyaluronic acid.
- hyaluronic acid hyaluronic acid that is not substantially chemically modified may be used, or chemically modified hyaluronic acid may be used.
- chemically modified hyaluronic acid examples include sodium carboxymethyl hyaluronate, hydroxypropyltrimonium hyaluronate, hydrolyzed alkyl hyaluronate (C12-13) glyceryl, propylene glycol hyaluronate, sodium acetylated hyaluronate, and the like. It is done. Chemically modified hyaluronic acid may be used alone or in combination of two or more.
- the hyaluronic acid content in the polymer contained in the lyophilized body is not particularly limited as long as it is 50% by mass or more, but is preferably 60% by mass or more, more preferably 80%. The mass% or more is mentioned.
- the content of hyaluronic acid in the polymer may be substantially 100% by mass.
- the content is not particularly limited as long as it is 50% by mass or less. While improving the handling of the patch, it has excellent adhesiveness to stick to the oral mucosa even when there is a lot of moisture and saliva on the oral mucosal surface, and shows the elasticity by including moisture and saliva after application, so that the application site is physically From the viewpoint of suitably exhibiting the property of enhancing the protective effect and the property of remaining at the applied site for a long time, it is preferably 40% by mass or less, more preferably 20% by mass or less.
- divalent alginate such as carboxymethyl cellulose, hydroxypropyl cellulose, cellulose nanofiber, polyacrylic acid, agarose, and calcium is more preferable.
- Another polymer may be used individually by 1 type and may be used in combination of 2 or more type.
- the content per unit area of hyaluronic acid contained in the lyophilized body is not particularly limited, while improving the handleability of the oral mucosa patch, Excellent stickiness to stick to the oral mucosa even when there is a lot of saliva, characteristics to enhance the effect of physically protecting the sticking site by including moisture and saliva after sticking, and long time application to the sticking site From the viewpoint of suitably exerting the remaining characteristics, for example, 0.1 mg / cm 2 or more, preferably about 0.5 to 100 mg / cm 2 , more preferably about 1 to 50 mg / cm 2 , and further preferably 2 to 25 mg. / Cm 2 , even more preferably about 3 to 25 mg / cm 2 , particularly preferably about 3 to 10 mg / cm 2 .
- the content of the polymer contained in the lyophilized body is not particularly limited as long as it is 20% by mass or more. However, even if the oral mucosa surface has a lot of moisture and saliva while improving the handleability of the oral mucosa patch, Suitable for sticking to mucous membranes, characteristics that enhance the effect of physically protecting the sticking part by including moisture and saliva after sticking, and characteristics that remain on the sticking part for a long time From the viewpoint of exhibiting, it is preferably 30% by mass or more, more preferably 50% by mass or more, further preferably 65% by mass or more, and still more preferably 75% by mass or more.
- the content of the polymer contained in the lyophilized product may be substantially 100% by mass.
- the freeze-dried product may further contain other components in addition to the polymer.
- Other components are not particularly limited as long as they do not inhibit the effects of the present invention, and examples include sugars, polyhydric alcohols, acids (acids different from hyaluronic acid), and the like.
- the freeze-dried product contains at least one of sugar and polyhydric alcohol
- the freeze-dried product becomes stronger and the handling property of the oral mucosa patch is further improved.
- moisture content or saliva after sticking shows more favorable elasticity, and raises the effect which protects a sticking site
- it can be expected to have an excellent sticking property that sticks to the oral mucosa and an effect that suitably exhibits the property of remaining at the sticking site for a long time.
- the freeze-dried product contains an acid
- the gel-like product formed by containing moisture and saliva after application exhibits better elasticity and further enhances the effect of physically protecting the application site.
- even when there is a lot of moisture and saliva on the oral mucosal surface it can be expected that the excellent sticking property to stick to the oral mucosa and the property of remaining on the sticking site for a long time are more suitably exhibited.
- the sugar is not particularly limited. Sugar, maltooligosaccharide, soybean oligosaccharide, xylooligosaccharide, etc.), ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, dextrin and the like.
- One type of sugar may be used alone, or two or more types may be used in combination.
- “sugar” does not include liquid polyhydric alcohol at 25 ° C., and the liquid polyhydric alcohol is included in “polyhydric alcohol” described later.
- the polyhydric alcohol is not particularly limited, but preferably glycerins such as glycerin and diglycerin; propylene glycols such as propylene glycol and dipropylene glycol; 1,3-propanediol, butanediol (1,3- Butanediol, 1,4-butanediol, etc.), 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol; ethylene glycols such as ethylene glycol, diethylene glycol, triethylene glycol, and polyethylene glycol More preferably, glycerin, diglycerin, propylene glycol, 1,3-butanediol, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, polyethylene Recall 1000, polyethylene glycol 1500, polyethylene glycol 6000, polyethylene glycol 20000,1,3- propanediol, 1,2-pentanediol,
- the content of the sugar or polyhydric alcohol in the lyophilized body (the total content if both are included) is not particularly limited as long as it is 80% by mass or less, but the handling property of the oral mucosa patch is not limited.
- the gel-like material formed with moisture and saliva after application will further enhance the effect of physically protecting the applied site, and will stick to the oral mucosa even when there is a lot of moisture and saliva on the oral mucosa surface From the viewpoint of suitably exhibiting excellent sticking property and the property of remaining at the sticking site for a long time, it is preferably 70% by weight or less, more preferably 50% by weight or less, further preferably 35% by weight or less, and still more preferably. 25 mass% or less is mentioned.
- the lower limit of the content is usually about 1% by mass.
- the acid different from hyaluronic acid is not particularly limited as long as it is acidic when mixed with water, and either an inorganic acid or an organic acid can be used.
- the inorganic acid include phosphoric acid, hydrochloric acid, sulfuric acid, nitric acid, perchloric acid, and carbonic acid, and preferably phosphoric acid, hydrochloric acid, and sulfuric acid.
- organic acids include monocarboxylic acids such as formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and lipoic acid; dicarboxylic acids such as succinic acid, phthalic acid, fumaric acid, oxalic acid, malonic acid, and glutaric acid.
- Acids such as glycolic acid, citric acid, lactic acid, pyruvic acid, malic acid, tartaric acid and salicylic acid; polyhydroxy acids such as glucono- ⁇ -lactone and lactopionic acid; acidic amino acids such as glutamic acid and aspartic acid; (Registered trademark, methyl carboxymethylphenylaminocarboxypropylphosphonate) and the like; ascorbic acid such as ascorbic acid, ethyl ascorbate, ascorbic acid glucoside or derivatives thereof, preferably phosphoric acid, ascorbic acid, citric acid, Glycolic acid, lactic acid, malic acid, tartar
- acids salicylic acid, ethyl ascorbate, ascorbic acid glucoside, glucono- ⁇ -lactone, and lactopionic acid.
- An acid may be used individually by 1 type and may be used in combination of 2 or more type.
- the acid content in the lyophilized product is not particularly limited, and examples include an amount in which the pH of the aqueous solution measured by the following measurement method is in the range of 1.9 to 5.2.
- aqueous solution is prepared by dissolving all ionic components in the lyophilized body containing 1 g of hyaluronic acid in water to 200 mL, and the pH of the obtained aqueous solution is measured.
- sugar and polyhydric alcohol are not ionic components, they are not mixed in an aqueous solution for measuring pH.
- steroid inflammatory agents such as dexamethasone and triamlosinolone acetonide
- anti-inflammatory agents such as glycyrrhizic acid and methyl salicylate, sodium azulene sulfonate, allantoin, sofalcone, rebamipide, narsgen (registered) Trademarks: Wound healing agents such as carboxy methylphenylaminocarboxypropylphosphonate methyl), bactericides such as cetylpyridinium chloride, cetylpyridinium chloride, chlorhexidine gluconate, popidone iodine, cionel, thymol, zinc chloride, zinc sulfate, zinc picolinate , Zinc compounds such as zinc gluconate and zinc acetate, fragrances such as L-menthol, vitamins such as vitamin B2 and vitamin E, animal or plant, herbal extracts and extracts, active ingredients such as blood flow promoters
- the oral mucosal patch of the present invention has excellent adhesive properties that stick to the oral mucosa even when there is a lot of moisture and saliva on the surface of the oral mucosa, and has the property of remaining on the applied site for a long time.
- the oral mucosa patch contains an active ingredient or the like, the active ingredient can be released in the oral cavity over a long period of time. Therefore, the oral mucosa patch of the present invention can also be used for the prevention or treatment of oral diseases such as alveolar pyorrhea, gingivitis, stomatitis, cheilitis, and oral mucositis.
- the oral mucosa patch of the present invention has excellent adhesive properties to stick to the oral mucosa even when there is a lot of moisture and saliva on the surface of the oral mucosa, and has characteristics that can control the dissolution time in the oral cavity.
- the oral mucosa patch of the present invention contains an allergen protein, it can also be used for specific desensitization therapy applied to the oral mucosa.
- the oral mucosa patch of the present invention has excellent adhesive properties to stick to the oral mucosa even when there is a lot of moisture and saliva on the surface of the oral mucosa, and has the property of remaining on the applied site for a long time,
- the oral mucosa patch of the present invention contains a systemic active ingredient and the like, the systemic active ingredient is transferred directly to the systemic circulation without passing through the liver via the oral mucosa, so that the whole body can be efficiently treated. Sexual active ingredients can be absorbed into the body. Therefore, the oral mucosa patch of the present invention can also be used for oral cavity mucosal absorption preparations applied to the oral mucosa.
- the thickness of the lyophilized body is not particularly limited, but when the oral mucosa patch is composed of a single layer of lyophilized body, it is preferably about 0.05 to 10 mm. In addition, when the oral mucosa patch is a laminate of a lyophilized product and a base material described later, the thickness of the lyophilized product is preferably about 0.02 to 10 mm. In addition, a freeze-dried body prepared by freeze-drying can be thinned by compression to obtain an oral mucosa patch.
- the area of the adhesive surface to the oral mucosa can be appropriately set according to the application site and the like, for example, about 0.2 to 50 cm 2 .
- the shape of the adhesion surface to the oral mucosa is not particularly limited, and examples thereof include a circle, an ellipse, a polygon (such as a triangle, a quadrangle, a pentagon, and a hexagon), a star, and an indefinite shape.
- the oral mucosa patch 10 of the present invention may be composed of a single layer of a lyophilized body 1 as shown in FIG. 1, for example, or as shown in FIG. You may be comprised by the multilayer provided with the freeze-dried body 1 laminated
- FIG.1 and FIG.2 the surface of the freeze-dried body 1 comprises the adhesion surface 10a with an oral mucosa.
- the oral mucosa patch of the present invention is provided with a base material, further improving the handleability of the oral mucosa patch, and having excellent adhesive properties for sticking to the oral mucosa even when the amount of water on the oral mucosa surface is large
- a base material that has high mechanical strength and water resistance as a material constituting the base material, and is inferior to sticking to a wet hand or the like than a lyophilized body containing hyaluronic acid, such an effect can be obtained. It becomes possible to exhibit suitably.
- the material constituting the base material is not particularly limited, but from the viewpoint of exerting such an effect, the above-mentioned other polymers and those obtained by adding polyhydric alcohol to other polymers are preferable.
- a lyophilized product of the above-mentioned other polymer as a base material, such an effect can be suitably exhibited.
- a material constituting the substrate particularly preferably, a freeze-dried product of an aqueous solution containing other polymers such as divalent alginate such as methylcellulose, hydroxypropylmethylcellulose, cellulose nanofiber, agarose, calcium, etc., and these polymers and molecular weight May be a freeze-dried product of an aqueous solution containing 1000 or more polyethylene glycol.
- Other polymers may be used alone or in combination of two or more, including hyaluronic acid (less than 50%).
- hyaluronic acid and the above-mentioned other polymer as a base material, it is possible to suitably exhibit such an effect.
- the material constituting the substrate include hyaluronic acid, other polymers described above, biodegradable polymers such as polylactic acid, and other polymers added with a plasticizer such as a polyhydric alcohol.
- Hyaluronic acid and the plasticizer to be added with another polymer may be used alone or in combination of two or more.
- the thickness of the substrate is not particularly limited, but is preferably 0.0001 to 10 mm, more preferably 0.0002 to 5 mm, or 0.01 to 10 mm. Can be mentioned.
- the oral mucosa patch of the present invention can suitably protect the oral mucosal surface, it can be suitably used for the prevention or treatment of oral mucosal diseases.
- the oral mucosal disease is not particularly limited, and includes those caused by stomatitis or cancer treatment.
- the application site of the oral mucosa patch of the present invention is not particularly limited as long as it is an oral mucosa. Moreover, you may eat and drink in the state in which the oral mucosa adhesive material of this invention was affixed on the oral mucosa.
- the method for producing the oral mucosa patch of the present invention is not particularly limited, and includes, for example, a step of preparing an aqueous solution containing the above-mentioned polymer and a step of freeze-drying the aqueous solution.
- hyaluronic acid Is a method using 50% by mass or more.
- the details of hyaluronic acid and other polymers, the content of each component, etc. are as described above. Moreover, what is necessary is just to adjust about content of the other polymer in the aqueous solution containing a polymer, and hyaluronic acid so that it may become these content in the above-mentioned oral mucosa patch.
- the oral mucosa patch of the present invention is composed of a multilayer comprising a base material and a lyophilized body laminated on the base material
- the base material is made of other polymer as described above.
- a lyophilized body either one of an aqueous solution of another polymer and an aqueous polymer solution containing hyaluronic acid is frozen, and the other aqueous solution is placed on the frozen body placed in the container.
- a multi-layered oral mucosa patch can be produced by a method of freeze-drying both.
- the substrate is composed of another polymer film as described above
- an aqueous polymer solution containing hyaluronic acid is poured into a container, the film is placed on the container, and then freeze-dried.
- a method is mentioned.
- a multi-layered oral mucosa patch can be produced by laminating a polymer aqueous solution containing hyaluronic acid on a substrate placed in a container and freeze-drying the polymer aqueous solution in that state. .
- Hyaluronic acid (2.3 million): Sodium hyaluronate, trade name “HYALURONSAN HA-LQSH” (product display: molecular weight 1.6 million to 2.9 million, average molecular weight 2.3 million, intrinsic viscosity 25.0 to 40.0 dL / g)
- Hyaluronic acid (1.6 million): Sodium hyaluronate, trade name “HYALURONSAN HA-LQH” manufactured by Kewpie Co., Ltd.
- Hyaluronic acid (1,200,000): Sodium hyaluronate, trade name “Hyaluronic Sun HA-LQ” manufactured by Kewpie Co., Ltd.
- Product indication molecular weight 85-1600,000; average molecular weight 1,200,000, intrinsic viscosity 15.0-25.0 dL / g
- Hyaluronic acid 600,000: Sodium hyaluronate, trade name “Hyaluronic acid FCH-60” manufactured by Kikkoman Biochemifa Co., Ltd.
- Hyaluronic acid (350,000): Hyaluronic acid, trade name “Hyaluronic acid HA-LF-P” manufactured by Kewpie Co., Ltd. (product indication: molecular weight 200,000 to 500,000, average molecular weight 350,000) (reagents used in the examples) (Measured value of intrinsic viscosity 8.7 dL / g) Hyaluronic acid (100,000): Sodium hyaluronate, trade name “Hyaluronic acid FCH-SU” manufactured by Kikkoman Biochemifa Co., Ltd.
- Carboxymethylcellulose Sodium carboxycellulose, trade name “Serogen F-BSH-12” manufactured by Daiichi Kogyo Seiyaku Co., Ltd.
- Methylcellulose Trade name “Methylcellulose SM-4000” manufactured by Shin-Etsu Chemical Co., Ltd.
- Hydroxypropyl methylcellulose trade name “Hypromellose 65SH-4000” manufactured by Shin-Etsu Chemical Co., Ltd. Hydroxypropylcellulose: Nippon Soda Co., Ltd.
- Gelatin Brand name “Gelatin 21” manufactured by Nitta Gelatin Co., Ltd.
- Xylitol Xylitol (special grade) manufactured by Wako Pure Chemical Industries, Ltd. Sorbitol: D (+)-sorbitol (first grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Trehalose Trehalose dihydrate (special grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Isomalt-oligosaccharide Trade name “Panolap” manufactured by Hayashibara Co., Ltd.
- Lactose fructose oligosaccharide Trade name “Fruit Oligo 700” manufactured by Hayashibara Galactooligosaccharide: Product name “Oligomate 55N” manufactured by Yakult Pharmaceutical Co., Ltd.
- Xylooligosaccharide Product name “Xylooligosaccharide 70L” manufactured by Product Food Saens Co., Ltd.
- Fructooligosaccharide Trade name “Mayoligo P (liquid)” manufactured by Meiji Food Materia Co., Ltd.
- Glycerin Glycerin (special grade) manufactured by Wako Pure Chemical Industries, Ltd. Diglycerin: Diglycerin manufactured by Wako Pure Chemical Industries, Ltd.
- Phosphoric acid phosphoric acid (special grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Citric acid Citric acid (special grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Lactic acid DL-lactic acid (special grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Vitamin C L (+)-ascorbic acid (special grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Proteoglycan Product name “Proteoglycan F” manufactured by Ichimaru Falcos Co., Ltd.
- Hyaluronic acid 800,000; hyabest (J): Sodium hyaluronate, trade name “Hyabest (J)” manufactured by Kewpie Co., Ltd.
- Product indication molecular weight 600,000 to 1,200,000, average molecular weight 800,000
- Measured value of intrinsic viscosity of the used reagent 14.1 dL / g
- Sodium carboxymethyl hyaluronate trade name “Hyaro Catch” manufactured by Kewpie Co., Ltd.
- Agarose Agarose III manufactured by Wako Pure Chemical Industries, Ltd.
- Alginic acid sodium alginate 500-600 (first grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Crystalline cellulose trade name “Theorus KG-1000” manufactured by Asahi Kasei Corporation Mannitol: D (-)-mannitol (special grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Polyethylene glycol 1000 polyethylene glycol 1000 (bulk) manufactured by Wako Pure Chemical Industries, Ltd.
- Polyethylene glycol 400 Polyethylene glycol 400 (first grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Calcium chloride Calcium chloride (special grade) manufactured by Wako Pure Chemical Industries, Ltd.
- Polylactic acid film Polylactic acid film (thickness 0.0002 mm) manufactured by Tsukioka Film Pharmaceutical Co., Ltd.
- Examples 1 to 6 Manufacture of oral mucosa patch
- hyaluronic acid having the molecular weight shown in Table 1 was uniformly dissolved in water to prepare a hyaluronic acid aqueous solution.
- concentration of hyaluronic acid in the hyaluronic acid aqueous solution was 10 mg / ml, respectively.
- the obtained aqueous solution of hyaluronic acid was put in a plastic petri dish having a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2, and was placed in a freezer at ⁇ 82 ° C. Frozen.
- the hyaluronic acid aqueous solution was freeze-dried in a petri dish at a pressure of 10 Pa or less (24 hours) to obtain a freeze-dried product of hyaluronic acid.
- the obtained freeze-dried product was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- D The oral mucosal patch was completely lost after rinsing.
- Examples 7 to 14 Manufacture of oral mucosa patch
- hyaluronic acid molecular weight 2.3 million
- hyaluronic acid in 9.1 ml of distilled water bottom area 9.1 cm 2
- the hyaluronic acid content per unit area is the value shown in Table 2.
- Examples 15 to 24 (Manufacture of oral mucosa patch) Dissolve hyaluronic acid and other polymers uniformly in water so that hyaluronic acid (molecular weight 2.3 million) is 80% by mass and the other polymers listed in Table 3 (polymers different from hyaluronic acid) are 20% by mass. To prepare an aqueous solution. At this time, the total concentration of hyaluronic acid and other polymers in the aqueous solution was 10 mg / ml, respectively.
- the obtained hyaluronic acid aqueous solution was placed in a plastic petri dish having a bottom area of 9.1 cm 2 so that the polymer content including hyaluronic acid per unit area was 7.5 mg / cm 2, and was placed in a freezer at ⁇ 82 ° C. And frozen.
- a freeze-dried product was obtained by freeze-drying the hyaluronic acid aqueous solution in a petri dish at a pressure of 10 Pa or less (24 hours).
- the obtained freeze-dried product was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- the properties of each oral mucosa patch, the sticking state to the oral mucosa, and the remaining state were evaluated. The results are shown in Table 3.
- Examples 25 to 28 Manufacture of oral mucosa patch
- hyaluronic acid molecular weight 2.3 million
- other polymers listed in Table 4 were 50% by mass
- the aqueous solution was prepared by uniformly dissolving hyaluronic acid and other polymers in water.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- Hyaluronic acid (molecular weight 2.3 million) was uniformly dissolved in water to prepare an aqueous solution having a concentration of 20 mg / ml.
- the obtained aqueous solution of hyaluronic acid was placed in a plastic petri dish having a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 10 mg / cm 2 and dried in a thermostat at 80 ° C. for 4 hours.
- a transparent and slightly hard hyaluronic acid film was obtained.
- the obtained film was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 60 ⁇ m.
- Hyaluron was prepared in the same manner as in Examples 15 to 24 except that the polymer described in Table 5 was 100% by mass and the polymer was uniformly dissolved in water to prepare an aqueous solution having a concentration of 10 mg / ml. An oral mucosa patch containing no acid was obtained. The thickness of the oral mucosa patch was about 0.75 cm each. Next, in the same manner as in Examples 1 to 6, the properties of each oral mucosa patch, the sticking state to the oral mucosa, and the remaining state were evaluated. The results are shown in Table 5.
- Comparative Examples 4, 5, 9, and 12 show the properties of Comparative Examples 4, 5, 9, and 12 in which the oral mucosa patch was adhered to the oral mucosa and remained after rinsing with double distilled water.
- Comparative Example 4 was a gel-like material having elasticity and thixotropy that easily collapses when touched with a tongue or the like.
- Comparative Examples 5, 9, and 12 were viscous materials.
- Example 1 which remained after rinsing with double distilled water was a gel-like product having good elasticity.
- Examples 29 to 35 Manufacture of oral mucosa patch
- An aqueous solution was prepared by uniformly dissolving hyaluronic acid and acid in water such that hyaluronic acid (molecular weight 2.3 million) and acid were in the proportions (mass%) shown in Table 6.
- the concentration of hyaluronic acid in the aqueous solution was 10 mg / ml.
- the obtained aqueous hyaluronic acid solution was placed in a plastic petri dish with a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2 and frozen in a freezer at ⁇ 82 ° C. .
- the petri dish was freeze-dried (24 hours) with a hyaluronic acid aqueous solution at a pressure of 10 Pa or less to obtain a freeze-dried product of acid-containing hyaluronic acid.
- the obtained freeze-dried product was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- the properties of each oral mucosa patch, the sticking status of each oral mucosa patch to the oral mucosa, and the remaining status were evaluated. The results are shown in Table 6.
- the oral mucosa patch of Examples 29 to 35 contained an acid in the lyophilized body, the oral mucosa patch (gel) after 10 minutes of sticking showed high elasticity.
- Examples 36 to 48 (Manufacture of oral mucosa patch) Prepare an aqueous solution by uniformly dissolving hyaluronic acid and sugar / polyhydric alcohol in water so that the ratio (mass%) of hyaluronic acid (molecular weight 2.3 million) and sugar / polyhydric alcohol is as shown in Table 7. did. At this time, the concentration of hyaluronic acid in the aqueous solution was 10 mg / ml. The obtained aqueous hyaluronic acid solution was placed in a plastic petri dish with a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2 and frozen in a freezer at ⁇ 82 ° C.
- the oral mucosa patches of Examples 36 to 48 contained sugar in the lyophilized body, so that the properties of the oral mucosa patches were imparted and the handleability was further improved. Moreover, the oral mucosa patch (gel-like material) 10 minutes after sticking showed high elasticity.
- Hyaluronic acid molecular weight 2,300,000
- other polymer, and galactooligosaccharide are dissolved in water so that hyaluronic acid, other polymer, and galactooligosaccharide are uniformly dissolved in water so that the ratio (mass%) shown in Table 8 is obtained.
- the ratio (mass%) shown in Table 8 was obtained.
- the total concentration of hyaluronic acid and other polymers in the aqueous solution was 10 mg / ml, respectively.
- the obtained hyaluronic acid aqueous solution was placed in a plastic petri dish having a bottom area of 9.1 cm 2 so that the polymer content including hyaluronic acid per unit area was 7.5 mg / cm 2, and was placed in a freezer at ⁇ 82 ° C. And frozen.
- the aqueous hyaluronic acid solution was lyophilized in a petri dish at a pressure of 10 Pa or less (24 hours) to obtain a lyophilized product of other polymer and galactooligosaccharide-containing hyaluronic acid.
- the obtained freeze-dried product was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- Example 53 to Example 62 Manufacture of oral mucosa patch
- An aqueous solution was prepared by uniformly dissolving hyaluronic acid, sugar, and acid in water such that hyaluronic acid (molecular weight 2.3 million), sugar, and acid were in the proportions (mass%) shown in Table 9.
- the concentration of hyaluronic acid in the aqueous solution was 10 mg / ml.
- the obtained aqueous hyaluronic acid solution was placed in a plastic petri dish with a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2 and frozen in a freezer at ⁇ 82 ° C. .
- the aqueous solution of hyaluronic acid was freeze-dried in a petri dish at a pressure of 10 Pa or less (24 hours) to obtain a freeze-dried product of acid and sugar-containing hyaluronic acid.
- the obtained freeze-dried product was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- the oral mucosa patches of Examples 53 to 62 contained sugar and acid in the lyophilized product, so that the properties of the oral mucosa patches were imparted and the handleability was further improved. Moreover, the oral mucosa patch (gel-like material) 10 minutes after sticking showed high elasticity.
- Example 63 to Example 65 Manufacture of oral mucosa patch
- Hyaluronic acid (molecular weight 2.3 million) was uniformly dissolved in water to prepare a hyaluronic acid aqueous solution having a concentration of 10 mg / ml.
- the obtained aqueous solution of hyaluronic acid was put in a plastic petri dish having a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2, and was placed in a freezer at ⁇ 82 ° C. Frozen.
- an aqueous solution having a concentration of 10 mg / ml was prepared by uniformly dissolving the polymer in water so that the polymer described in Table 10 was 100% by mass, and the polymer content was on the frozen hyaluronic acid aqueous solution. It was put to 2.0 mg / cm 2 and frozen in a freezer at ⁇ 82 ° C. Next, this frozen aqueous solution was freeze-dried (24 hours) in a petri dish at a pressure of 10 Pa or less to obtain an oral mucosa patch having two layers of freeze-dried body / base material. The thickness of each oral mucosa patch was about 0.95 cm.
- the oral mucosa patches of Examples 61 to 63 have a configuration in which a lyophilized product containing hyaluronic acid is laminated on another polymer layer (base material) having low adhesiveness to the oral mucosa. Therefore, when the oral mucosa patch was applied to the oral mucosa, even if the hands were wet, it did not stick to the lyophilized material of the base material, and the applicability to the oral cavity was particularly excellent.
- Example 66 to 68 Manufacture of oral mucosa patch
- hyaluronic acid described in Table 11 was uniformly dissolved in water to prepare a hyaluronic acid aqueous solution.
- concentration of hyaluronic acid in the hyaluronic acid aqueous solution was 10 mg / ml, respectively.
- the obtained aqueous solution of hyaluronic acid was put in a plastic petri dish having a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2, and was placed in a freezer at ⁇ 82 ° C. Frozen.
- the hyaluronic acid aqueous solution was freeze-dried in a petri dish at a pressure of 10 Pa or less (24 hours) to obtain a freeze-dried product of hyaluronic acid.
- the obtained freeze-dried product was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- Example 69 to 72 (Manufacture of oral mucosa patch) Dissolve hyaluronic acid and other polymers uniformly in water so that hyaluronic acid (molecular weight 2.3 million) is 80% by mass and other polymers listed in Table 12 (polymers different from hyaluronic acid) are 20% by mass. (Crystalline cellulose was uniformly dispersed) to prepare an aqueous solution.
- Example 71 after preparing a uniform aqueous solution of hyaluronic acid and alginic acid, 0.2 part by weight of calcium chloride was added to 1 part by weight of alginic acid to uniformly dissolve and freeze-dry.
- the total concentration of hyaluronic acid and other polymers in the aqueous solution was 10 mg / ml, respectively.
- the obtained hyaluronic acid aqueous solution was placed in a plastic petri dish having a bottom area of 9.1 cm 2 so that the polymer content including hyaluronic acid per unit area was 7.5 mg / cm 2, and was placed in a freezer at ⁇ 82 ° C. And frozen.
- a freeze-dried product was obtained by freeze-drying the hyaluronic acid aqueous solution in a petri dish at a pressure of 10 Pa or less (24 hours).
- the obtained freeze-dried product was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- the properties of each oral mucosa patch, the sticking state to the oral mucosa, and the remaining state were evaluated. The results are shown in Table 12.
- Example 73 to Example 75 Manufacture of oral mucosa patch
- hyaluronic acid Molecular weight 2.3 million
- sugar / polyhydric alcohol as shown in Table 13.
- the concentration of hyaluronic acid in the aqueous solution was 10 mg / ml.
- the obtained aqueous hyaluronic acid solution was placed in a plastic petri dish with a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2 and frozen in a freezer at ⁇ 82 ° C. .
- the aqueous solution of hyaluronic acid was lyophilized in a petri dish at a pressure of 10 Pa or less (24 hours) to obtain a freeze-dried product of hyaluronic acid containing sugar / polyhydric alcohol.
- the obtained freeze-dried product was used as an oral mucosa patch.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- Hyaluronic acid (molecular weight 2.3 million) was uniformly dissolved in water to prepare a hyaluronic acid aqueous solution having a concentration of 10 mg / ml.
- the obtained aqueous solution of hyaluronic acid was put in a plastic petri dish having a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2, and was placed in a freezer at ⁇ 82 ° C. Frozen.
- an aqueous solution was prepared by uniformly dissolving the other polymer and polyethylene glycol 1000 in water such that the other polymer and polyethylene glycol 1000 were in the proportions (mass%) shown in Table 14.
- the concentration of the other polymer in this aqueous solution was 10 mg / ml.
- This aqueous solution was placed on a frozen hyaluronic acid aqueous solution so that the content of other polymers was 1.0 mg / cm 2, and frozen in a freezer at ⁇ 82 ° C.
- this frozen aqueous solution was freeze-dried (24 hours) in a petri dish at a pressure of 10 Pa or less to obtain an oral mucosa patch having two layers of freeze-dried body / base material.
- each oral mucosa patch was about 0.85 cm.
- the oral mucosa patch of Examples 76 to 80 has a structure in which a lyophilized body containing hyaluronic acid is laminated on another polymer layer (base material) having low adhesiveness to the oral mucosa. Therefore, when the oral mucosa patch was applied to the oral mucosa, even if the hands were wet, it did not stick to the lyophilized material of the base material, and the applicability to the oral cavity was particularly excellent.
- Example 81 to 84 (Manufacture of oral mucosa patch) Cellulose nanofiber 10 mg / ml concentration aqueous solution, cellulose nanofiber 10 mg / ml concentration and glycerol 40 mg / ml concentration aqueous solution, agarose 10 mg / ml concentration aqueous solution, agarose 10 mg / ml concentration and glycerol 40 mg / ml concentration Each aqueous solution was prepared, each aqueous solution was applied onto a polyethylene terephthalate film, and dried in a thermostatic bath at 80 ° C. for 1 hour to obtain a film-like product (base material) having a thickness of about 50 ⁇ m.
- hyaluronic acid (molecular weight 2.3 million) was uniformly dissolved in water to prepare a hyaluronic acid aqueous solution having a concentration of 10 mg / ml.
- the obtained hyaluronic acid aqueous solution was placed in a plastic petri dish having a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2, and then the diameter was 3.4 cm.
- Each film-like product cut with a punch of (a base material using other polymers and glycerin shown in Table 15) was placed on a hyaluronic acid aqueous solution and frozen in a freezer at -82 ° C.
- the aqueous solution of hyaluronic acid was lyophilized in a petri dish at a pressure of 10 Pa or less (24 hours) to obtain an oral mucosa patch having two layers of lyophilized body / base material.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- the oral mucosa patches of Examples 81 to 84 have a structure in which a freeze-dried body containing hyaluronic acid is laminated on a base material having low adhesiveness to the oral mucosa. When sticking the oral mucosa patch, it was not particularly sticking to the lyophilized material of the base material even when the hands were wet, and was particularly excellent in applicability to the oral cavity.
- Example 85 to Example 87 Manufacture of oral mucosa patch
- An aqueous solution having a concentration of 10 mg / ml is prepared by uniformly dissolving alginic acid in water, this aqueous solution is applied onto a polyethylene terephthalate film, and dried in a thermostatic bath at 80 ° C. for 1 hour to obtain a film of alginic acid. Obtained.
- This film-like product is immersed in a 0.2% calcium chloride aqueous solution for 1 hour, then thoroughly washed with ion-exchanged water, and further dried in a constant temperature bath at 80 ° C. for 1 hour to form a film having a thickness of about 50 ⁇ m. Of calcium alginate was obtained.
- a film-like calcium alginate equivalent to 4 parts by weight of glycerin is impregnated into the film-like calcium alginate with respect to 1 part by weight of the calcium alginate film, and then a thermostat at 80 ° C.
- the film was dried for 1 hour to obtain a calcium alginate / glycerin film having a thickness of about 50 ⁇ m.
- hyaluronic acid molecular weight 2.3 million
- hyaluronic acid aqueous solution was placed in a plastic petri dish having a bottom area of 9.1 cm 2 so that the hyaluronic acid content per unit area was 7.5 mg / cm 2, and then the diameter was 3.4 cm.
- Each film-like product (base material) or polylactic acid film (base material) cut with a punch of was placed on a hyaluronic acid aqueous solution and frozen in a freezer at -82 ° C.
- Table 16 shows the contents of other polymers and glycerin used in each substrate.
- the aqueous solution of hyaluronic acid was lyophilized in a petri dish at a pressure of 10 Pa or less (24 hours) to obtain an oral mucosa patch having two layers of lyophilized body / base material.
- the thickness of the oral mucosa patch was about 0.75 cm each.
- the oral mucosa patches of Examples 85 to 87 have a structure in which a freeze-dried body containing hyaluronic acid is laminated on a base material having low adhesiveness to the oral mucosa. When sticking the oral mucosa patch, it was not particularly sticking to the lyophilized material of the base material even when the hands were wet, and was particularly excellent in applicability to the oral cavity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
項1. 口腔粘膜との接着面に、ポリマーを含む凍結乾燥体を備えた口腔粘膜貼付材であって、
前記凍結乾燥体中の前記ポリマーの含有量が、20質量%以上であり、
前記ポリマー中のヒアルロン酸の含有量が、50質量%以上である、口腔粘膜貼付材。
項2. 前記ヒアルロン酸の分子量が、1×105ダルトン以上である、項1に記載の口腔粘膜貼付材。
項3. 下記の測定方法によって測定される前記ヒアルロン酸の極限粘度が、3dL/g以上である、項1又は2に記載の口腔粘膜貼付材。
(極限粘度の測定法)
ヒアルロン酸50mgを量り、0.2mol/L塩化ナトリウム溶液に溶かして100mLとした液、並びに、この液10mL、15mL、及び20mLを量り、それぞれに0.2mol/L塩化ナトリウム溶液を加えて25mLとした液を、それぞれ試料溶液とする。各試料溶液と0.2mol/L塩化ナトリウム溶液について、日本薬局方 第17局の「一般試験法の2.53 粘度測定法の1. 第1法 毛細管粘度計法」の規定に準じた粘度測定法により30.0±0.1℃の環境で比粘度を測定し、還元粘度を算出する。還元粘度を縦軸に、ヒアルロン酸の濃度(g/100mL)を横軸にとってグラフを描き、各点を結ぶ直線と縦軸との交点から極限粘度を求める。
ただし、比粘度及び還元粘度は次式から求める。
比粘度=(試料溶液の流下秒数÷0.2mol/L塩化ナトリウム溶液の流下秒速)-1
還元粘度=比粘度÷ヒアルロン酸の濃度(g/100mL)
項4. 前記凍結乾燥体に含まれる前記ヒアルロン酸の含有量が、0.1mg/cm2以上である、項1~3のいずれかに記載の口腔粘膜貼付材。
項5. 基材と、この基材の上に積層された前記凍結乾燥体とを備える、項1~4のいずれかに記載の口腔粘膜貼付材。
項6. 前記凍結乾燥体が、前記ヒアルロン酸とは異なるポリマーを0質量%~20質量%含む、項1~5のいずれかに記載の口腔粘膜貼付材。
項7. 前記凍結乾燥体が、ヒアルロン酸とは異なる酸をさらに含んでいる、項1~6のいずれかに記載の口腔粘膜貼付材。
項8. 前記凍結乾燥体が、糖及び多価アルコールの少なくとも一方をさらに含んでいる、項1~7のいずれかに記載の口腔粘膜貼付材。
項9. 口腔粘膜疾患の予防または治療に使用される、項1~8のいずれかに記載の口腔粘膜貼付材。
項10. 前記口腔粘膜疾患が、がん治療に起因する、項9に記載の口腔粘膜貼付材。
項11. 口腔粘膜に適用される減感作療法に使用される、項1~8のいずれかに記載の口腔粘膜貼付材。
項12. 口腔粘膜に適用される経口腔粘膜吸収製剤に使用される、項1~8のいずれかに記載の口腔粘膜貼付材。
項13. 項1~12のいずれかに記載の口腔粘膜貼付材の製造方法であって、
ポリマーを含む水溶液を用意する工程と、
前記水溶液を凍結乾燥する工程と、
を備えており、
前記ポリマーとして、ヒアルロン酸が50質量%以上含まれるものを用いる、口腔粘膜貼付材の製造方法。
ヒアルロン酸50mgを量り、0.2mol/L塩化ナトリウム溶液に溶かして100mLとした液、並びに、この液10mL、15mL、及び20mLを量り、それぞれに0.2mol/L塩化ナトリウム溶液を加えて25mLとした液を、それぞれ試料溶液とする。各試料溶液と0.2mol/L塩化ナトリウム溶液について、日本薬局方 第17局の「一般試験法の2.53 粘度測定法の1. 第1法 毛細管粘度計法」の規定に準じた粘度測定法により30.0±0.1℃の環境で比粘度を測定し、還元粘度を算出する。還元粘度を縦軸に、ヒアルロン酸の濃度(g/100mL)を横軸にとってグラフを描き、各点を結ぶ直線と縦軸との交点から極限粘度を求める。なお、原料として使用されるヒアルロン酸には、通常、水分が数%程度含まれているが、上記式での「ヒアルロン酸の濃度」とは、乾燥ヒアルロン酸に換算した濃度を意味している。ただし、比粘度及び還元粘度は次式から求める。
比粘度=(試料溶液の流下秒数÷0.2mol/L塩化ナトリウム溶液の流下秒速)-1
還元粘度=比粘度÷ヒアルロン酸の濃度(g/100mL)
ヒアルロン酸1gを含む分量の凍結乾燥体に含まれる成分のうち、全てのイオン性成分を水に溶解して200mLとなるように水溶液を調製し、得られた水溶液のpHを測定する。なお、前述の糖や多価アルコールは、イオン性成分ではないため、pHを測定する水溶液には混合しない。
ヒアルロン酸(230万):ヒアルロン酸ナトリウム、キューピー株式会社製の商品名「HYALURONSAN HA-LQSH」(製品表示:分子量160万~290万、平均分子量230万、極限粘度25.0~40.0dL/g)
ヒアルロン酸(160万):ヒアルロン酸ナトリウム、キューピー株式会社製の商品名「HYALURONSAN HA-LQH」(製品表示:分子量120万~220万、平均分子量160万、極限粘度19.5~32.0dL/g)
ヒアルロン酸(120万):ヒアルロン酸ナトリウム、キューピー株式会社製の商品名「ヒアルロンサンHA-LQ」(製品表示:分子量85~160万;平均分子量120万、極限粘度15.0~25.0dL/g)
ヒアルロン酸(60万):ヒアルロン酸ナトリウム、キッコーマンバイオケミファ株式会社製の商品名「ヒアルロン酸 FCH-60」(製品表示:平均分子量50万~70万)
ヒアルロン酸(35万):ヒアルロン酸、キューピー株式会社製の商品名「ヒアルロン酸HA-LF-P」(製品表示:分子量20万~50万、平均分子量35万)(実施例に使用した試薬の極限粘度の測定値8.7dL/g)
ヒアルロン酸(10万):ヒアルロン酸ナトリウム、キッコーマンバイオケミファ株式会社製の商品名「ヒアルロン酸 FCH-SU」(製品表示:平均分子量5万~11万)
カルボキシメチルセルロース:カルボキシセルロースナトリウム、第一工業製薬株式会社製の商品名「セロゲンF-BSH-12」
メチルセルロース:信越化学工業株式会社製の商品名「メチルセルロースSM-4000」
ヒドロキシプロピルメチルセルロース:信越化学工業株式会社製の商品名「ヒプロメロース65SH-4000」
ヒドロキシプロピルセルロース:日本曹達株式会社製の商品名「ヒドロキシプロピルセルロースH」
ポリアクリル酸:Aldrich社製の商品名「Poly(acrlic acid):平均分子量~1,250,000」
ポリビニルピロリドン:和光純薬工業株式会社製の商品名「ポリビニルピロリドンK90(分子生物学用)」
プルラン:和光純薬工業株式会社製のプルラン(生化学用)
セルロースナノファイバー:第一工業製薬株式会社製の商品名「レオクリスタ(防腐剤無添加)」
アラビアゴム:和光純薬工業株式会社製のアラビアゴム(試薬)
ゼラチン:新田ゼラチン株式会社製の商品名「ゼラチン21」
キシリトール:和光純薬工業株式会社製のキシリトール(特級)
ソルビトール:和光純薬工業株式会社製のD(+)-ソルビトール(一級)
トレハロース:和光純薬工業株式会社製のトレハロース二水和物(特級)
イソマルトオリゴ糖:株式会社林原製の商品名「パノラップ」
乳糖果糖オリゴ糖:株式会社林原製の商品名「乳果オリゴ700」
ガラクトオリゴ糖:ヤクルト薬品工業株式会社製の商品名「オリゴメイト55N」
キシロオリゴ糖:物産フードサエンス株式会社製の商品名「キシロオリゴ糖70L」
フラクトオリゴ糖:株式会社明治フードマテリア製の商品名「メイオリゴP(液)」
グリセリン:和光純薬工業株式会社製のグリセリン(特級)
ジグリセリン:和光純薬株式会社製のジグリセリン(ガスクロマトグラフ用)
リン酸:和光純薬工業株式会社製のリン酸(特級)
クエン酸:和光純薬工業株式会社製のクエン酸(特級)
乳酸:和光純薬工業株式会社製のDL-乳酸(特級)
ビタミンC:和光純薬工業株式会社製のL(+)-アスコルビン酸(特級)
プロテオグリカン:一丸ファルコス株式会社製の商品名「プロテオグリカンF」
ヒアルロン酸(60万;HA-LQ60):ヒアルロン酸ナトリウム、キューピー株式会社製の商品名「HYALURONSAN HA-LQ60」(製品表示:分子量50万~75万、平均分子量60万、極限粘度10.0~14.0dL/g)
ヒアルロン酸(80万;ヒアベスト(J)):ヒアルロン酸ナトリウム、キューピー株式会社製の商品名「ヒアベスト(J)」(製品表示:分子量60万~120万、平均分子量80万)(実施例に使用した試薬の極限粘度の測定値14.1dL/g)
カルボキシメチルヒアルロン酸ナトリウム:キューピー株式会社製の商品名「ヒアロキャッチ」(製品表示:分子量80万~120万)
アガロース:和光純薬工業株式会社製のアガロースIII
アルギン酸:和光純薬工業株式会社製のアルギン酸ナトリウム500~600(一級)
結晶セルロース:旭化成株式会社製の商品名「セオラスKG-1000」
マンニトール:和光純薬工業株式会社製のD(-)-マンニトール(特級)
ポリエチレングリコール1000:和光純薬工業株式会社製のポリエチレングリコール1000(塊状)
ポリエチレングリコール400:和光純薬工業株式会社製のポリエチレングリコール400(一級)
塩化カルシウム:和光純薬工業株式会社製の塩化カルシウム(特級)
ポリ乳酸フィルム:ツキオカフィルム製薬株式会社製のポリ乳酸フィルム(厚さ0.0002mm)
(口腔粘膜貼付材の製造)
表1に記載の分子量を有する各ヒアルロン酸を、それぞれ、水中に均一に溶解して、ヒアルロン酸水溶液を調製した。このとき、ヒアルロン酸水溶液中のヒアルロン酸の濃度は、それぞれ10mg/mlとした。次に、得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、ヒアルロン酸の凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。
口腔粘膜貼付材の性状を以下の基準により評価した。結果を表1に示す。
(口腔粘膜貼付材の性状)
A:綿状の乾燥体で、ふんわりとして腰がない。
B:綿状の乾燥体で、ふんわりとしているが腰がある。
C:綿状の乾燥体で、柔軟性はあまりなく腰がある。
D:高密度のスポンジ状乾燥体で、柔軟性はあまりない。
E:綿状の乾燥体で、もろい。
上記で得られた各口腔粘膜貼付材を20mmφのポンチでカットし、100mlの蒸留水で口腔内をすすいで清潔にした口腔粘膜(口腔内の頬の内側であり、口腔粘膜表面に水分が多い状態)にそれぞれ貼り付けた。そのまま10分放置後、100mlの蒸留水で口腔内をすすぎ、更に30分後に100mlの蒸留水で口腔内をすすぎ、貼り付き10分後の貼り付き状況(貼り付き性)、及び2回蒸留水ですすいだ後の口腔粘膜貼付材の残存状況を以下の基準により評価した。結果を表1に示す。
A:口腔粘膜に口腔粘膜貼付材がしっかりと貼り付いており、口腔粘膜貼付材が水和して口腔粘膜を好適に保護できている。さらに、口腔粘膜貼付材の溶け出しは、ほとんどない。
B:口腔粘膜貼付材が貼り付いており、口腔粘膜貼付材が水和して口腔粘膜を保護できているが、口腔粘膜貼付材が溶け出していた。
C:貼り付け時には、口腔粘膜にしっかりと貼り付いていたが、口腔粘膜貼付材が水和してほとんど溶けだし、口腔粘膜を保護できていなかった。
D:貼り付け時に口腔粘膜にほとんど貼り付いておらず、10分後には口腔粘膜から剥離した。
A:すすいだ後も水和した口腔粘膜貼付材がほとんど残存しており、口腔粘膜を好適に保護できていた。
B:すすいだ後に水和した口腔粘膜貼付材が10分後よりも減ってはいたが、口腔粘膜を保護できていた。
C:すすいだ後に水和した口腔粘膜貼付材が10分後よりもかなり減っていたが、口腔粘膜を保護できていた。
D:すすいだ後に水和した口腔粘膜貼付材が完全になくなっていた。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)を用い、単位面積当たりのヒアルロン酸の含有量が表2に記載の値となるようにヒアルロン酸を9.1mlの蒸留水にプラスチックシャーレ(底面積が9.1cm2)中で均一に溶解して、-82℃の冷凍庫で凍結させたこと以外は、実施例1~6と同様にして、口腔粘膜貼付材を得た。口腔粘膜貼付材の厚みは、それぞれ約1.0cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表2に示す。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)が80質量%、表3に記載の他のポリマー(ヒアルロン酸とは異なるポリマー)が20質量%となるようにして、ヒアルロン酸と他のポリマーを水中に均一に溶解して水溶液を調製した。このとき、水溶液中のヒアルロン酸と他のポリマーの合計濃度は、それぞれ10mg/mlとした。得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸も含めたポリマーの含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表3に示す。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)が50質量%、表4に記載の他のポリマーが50質量%となるようにして、ヒアルロン酸と他のポリマーを水中に均一に溶解して水溶液を調製したこと以外は、実施例15~24と同様にして、口腔粘膜貼付材を得た。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表4に示す。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)を水中に均一に溶解して20mg/mlの濃度となる水溶液を調製した。この得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が10mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、80℃の恒温槽で4時間乾燥し、透明で少し硬いヒアルロン酸のフィルム体を得た。得られたフィルム体を口腔粘膜貼付材とした。この口腔粘膜貼付材の厚みは約60μmであった。
(口腔粘膜貼付材の製造)
テレグラフTG‐50KN(ミネベア株式会社製)と打錠用治具を用いて24KN/cm2の圧力をかけて、ヒアルロン酸(分子量230万)の錠剤を得た。得られた錠剤を口腔粘膜貼付材とした。錠剤の質量は150mg、大きさは10mmφ、厚みは約3mmであった。
ヒアルロン酸(分子量230万)の原末(粉末)をそのまま口腔粘膜貼付材とした。
比較例1の口腔粘膜貼付材(フィルム)は20mmφのポンチでカットして、比較例2の口腔粘膜貼付材(錠剤)はそのまま、比較例3の口腔粘膜貼付材(粉末)は25mgをそのまま、それぞれを100mlの蒸留水で口腔内をすすいで清潔にした口腔粘膜(口腔内の頬の内側であり、口腔粘膜表面に水分が多い状態)に貼り付けた。しかし、比較例1~3のいずれの口腔粘膜貼付材も水和はするものの、口腔粘膜に付着せず、10分後には口腔粘膜から剥がれていた。
(口腔粘膜貼付材の製造)
表5に記載のポリマーが100質量%となるようにして、ポリマーを水中に均一に溶解して10mg/ml濃度となる水溶液を調製したこと以外は、実施例15~24と同様にして、ヒアルロン酸を含有しない口腔粘膜貼付材を得た。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表5に示す。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)と酸が表6に記載の割合(質量%)となるようにして、ヒアルロン酸と酸を水中に均一に溶解して水溶液を調製した。このとき、水溶液中のヒアルロン酸の濃度は、それぞれ10mg/mlとした。得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。このシャーレを圧力10Pa以下においてヒアルロン酸水溶液を凍結乾燥(24時間)することにより、酸含有ヒアルロン酸の凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、各口腔粘膜貼付材の口腔粘膜への貼り付き状況、残存状況を評価した。結果を表6に示す。なお、実施例29~35の口腔粘膜貼付材は、凍結乾燥体に酸を含んでいるため、貼り付き10分後の口腔粘膜貼付材(ゲル状物)は高い弾性を示していた。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)と、糖/多価アルコールが表7に記載の割合(質量%)となるようにして、ヒアルロン酸と糖/多価アルコールを水中に均一に溶解して水溶液を調製した。このとき、水溶液中のヒアルロン酸の濃度は、それぞれ10mg/mlとした。得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、糖/多価アルコール含有ヒアルロン酸の凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表7に示す。なお、実施例36~実施例48の口腔粘膜貼付材は、凍結乾燥体に糖を含んでいるため、口腔粘膜貼付材の性状にコシが付与され、取扱性がさらに向上していた。また、貼り付き10分後の口腔粘膜貼付材(ゲル状物)は高い弾性を示していた。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)、他のポリマー、及びガラクオリゴ糖が表8に記載の割合(質量%)となるようにして、ヒアルロン酸と他のポリマー、ガラクオリゴ糖を水中に均一に溶解して水溶液を調製した。このとき、水溶液中のヒアルロン酸と他のポリマーの合計濃度は、それぞれ10mg/mlとした。得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸も含めたポリマーの含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、他のポリマー、及びガラクオリゴ糖含有ヒアルロン酸の凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表8に示す。なお、実施例49~52の口腔粘膜貼付材は、凍結乾燥体に糖を含んでいるため、口腔粘膜貼付材の性状にコシが付与され、取扱性がさらに向上していた。また、貼り付き10分後の口腔粘膜貼付材(ゲル状物)は高い弾性を示していた。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)、糖、及び酸が表9に記載の割合(質量%)となるようにして、ヒアルロン酸、糖、及び酸を水中に均一に溶解して水溶液を調製した。このとき、水溶液中のヒアルロン酸の濃度は、それぞれ10mg/mlとした。得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、酸、及び糖含有ヒアルロン酸の凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表9に示す。なお、実施例53~62の口腔粘膜貼付材は、凍結乾燥体に糖と酸を含んでいるため、口腔粘膜貼付材の性状にコシが付与され、取扱性がさらに向上していた。また、貼り付き10分後の口腔粘膜貼付材(ゲル状物)は高い弾性を示していた。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)を水中に均一に溶解して、10mg/ml濃度となるヒアルロン酸水溶液を調製した。次に、得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、表10に記載のポリマーが100質量%となるようにして、ポリマーを水中に均一に溶解して10mg/ml濃度となる水溶液を調製し、凍結したヒアルロン酸水溶液上にポリマー含有量が2.0mg/cm2となるように入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてこの凍結水溶液をシャーレ内で凍結乾燥(24時間)させることにより、凍結乾燥体/基材の2層からなる口腔粘膜貼付材を得た。口腔粘膜貼付材の厚みは、それぞれ約0.95cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表10に示す。なお、実施例61~実施例63の口腔粘膜貼付材においては、口腔粘膜に対する粘着性の低い他のポリマー層(基材)の上にヒアルロン酸を含む凍結乾燥体が積層された構成を備えているため、口腔粘膜に口腔粘膜貼付材を貼り付ける際に、手が湿っていても基材の凍結乾燥体に貼り付かず、口腔内への適用性に特に優れていた。
実施例63~65で作製した口腔粘膜貼付材を20mmφのポンチでカットし、口内炎を発症したボランティア3名の口腔粘膜(口腔内の頬の内側)にそれぞれ貼付した。貼付後、飲食はせずに通常の生活をした。その結果、ボランティア3名において、実施例63~65で作製したいずれの口腔粘膜貼付材は、患部に対する刺激、異物感等の不具合はなく、3時間以上にわたり患部を保護していた。
(口腔粘膜貼付材の製造)
表11に記載の各ヒアルロン酸を、それぞれ、水中に均一に溶解して、ヒアルロン酸水溶液を調製した。このとき、ヒアルロン酸水溶液中のヒアルロン酸の濃度は、それぞれ10mg/mlとした。次に、得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、ヒアルロン酸の凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表11に示す。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)が80質量%、表12に記載の他のポリマー(ヒアルロン酸とは異なるポリマー)が20質量%となるようにして、ヒアルロン酸と他のポリマーを水中に均一に溶解(結晶セルロースは均一に分散)して水溶液を調製した。実施例71は、ヒアルロン酸とアルギン酸の均一な水溶液を調製後、アルギン酸1重量部に対して塩化カルシウム0.2重量部を添加して均一に溶解して凍結乾燥する水溶液を調製した。水溶液中のヒアルロン酸と他のポリマーの合計濃度は、それぞれ10mg/mlとした。得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸も含めたポリマーの含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表12に示す。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)と、糖/多価アルコールが表13に記載の割合(質量%)となるようにして、ヒアルロン酸と糖/多価アルコールを水中に均一に溶解して水溶液を調製した。このとき、水溶液中のヒアルロン酸の濃度は、それぞれ10mg/mlとした。得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、糖/多価アルコール含有ヒアルロン酸の凍結乾燥体を得た。得られた凍結乾燥体を口腔粘膜貼付材とした。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表13に示す。なお、実施例73~実施例75の口腔粘膜貼付材は、凍結乾燥体に糖/多価アルコールを含んでいるため、口腔粘膜貼付材の性状にコシが付与され、取扱性がさらに向上していた。また、貼り付き10分後の口腔粘膜貼付材(ゲル状物)は高い弾性を示していた。
(口腔粘膜貼付材の製造)
ヒアルロン酸(分子量230万)を水中に均一に溶解して、10mg/ml濃度となるヒアルロン酸水溶液を調製した。次に、得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れ、-82℃の冷凍庫で凍結させた。次に、他のポリマー及びポリエチレングリコール1000が表14に記載の割合(質量%)となるようにして、他のポリマー及びポリエチレングリコール1000を水中に均一に溶解して水溶液を調製した。この水溶液中の他のポリマーの濃度は10mg/mlとした。この水溶液を凍結したヒアルロン酸水溶液上に他のポリマー含有量が1.0mg/cm2となるように入れ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてこの凍結水溶液をシャーレ内で凍結乾燥(24時間)させることにより、凍結乾燥体/基材の2層からなる口腔粘膜貼付材を得た。口腔粘膜貼付材の厚みは、それぞれ約0.85cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表14に示す。なお、実施例76~実施例80の口腔粘膜貼付材においては、口腔粘膜に対する粘着性の低い他のポリマー層(基材)の上にヒアルロン酸を含む凍結乾燥体が積層された構成を備えているため、口腔粘膜に口腔粘膜貼付材を貼り付ける際に、手が湿っていても基材の凍結乾燥体に貼り付かず、口腔内への適用性に特に優れていた。
(口腔粘膜貼付材の製造)
セルロースナノファイバー10mg/ml濃度となる水溶液、セルロースナノファイバー10mg/ml濃度とグリセリン40mg/ml濃度となる水溶液、アガロース10mg/ml濃度となる水溶液、アガロース10mg/ml濃度とグリセリン40mg/ml濃度となる水溶液をそれぞれ調製し、それぞれの水溶液をポリエチレンテレフタレートフィルム上に塗布し、80℃の恒温槽中で1時間乾燥して、厚み約50μmのフィルム状物(基材)を得た。次に、ヒアルロン酸(分子量230万)を水中に均一に溶解して、10mg/ml濃度となるヒアルロン酸水溶液を調製した。次に、得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れた後、直径3.4cmのポンチでカットした各フィルム状物(表15に示す他のポリマー及びグリセリンを用いた基材)をヒアルロン酸水溶液上にのせ、-82℃の冷凍庫で凍結させた。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、凍結乾燥体/基材の2層からなる口腔粘膜貼付材を得た。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表15に示す。なお、実施例81~実施例84の口腔粘膜貼付材においては、口腔粘膜に対する粘着性の低い基材の上にヒアルロン酸を含む凍結乾燥体が積層された構成を備えているため、口腔粘膜に口腔粘膜貼付材を貼り付ける際に、手が湿っていても基材の凍結乾燥体に貼り付かず、口腔内への適用性に特に優れていた。
(口腔粘膜貼付材の製造)
アルギン酸を水中に均一に溶解して10mg/ml濃度となる水溶液を調製し、この水溶液をポリエチレンテレフタレートフィルム上に塗布し、80℃の恒温槽中で1時間乾燥して、アルギン酸のフィルム状物を得た。このフィルム状物を0.2%塩化カルシウム水溶液に1時間浸漬した後、イオン交換水にて十分に洗浄して、更に80℃の恒温槽中で1時間乾燥して、厚み約50μmのフィルム状のアルギン酸カルシウムを得た。別に、同様にフィルム状のアルギン酸カルシウムを調製した後、アルギン酸カルシウムフィルム1重量部に対してグリセリン4重量に相当する10%グリセリン水溶液をフィルム状のアルギン酸カルシウムに含浸させた後、80℃の恒温槽中で1時間乾燥して、厚み約50μmのフィルム状のアルギン酸カルシウム/グリセリンを得た。次に、ヒアルロン酸(分子量230万)を水中に均一に溶解して、10mg/ml濃度となるヒアルロン酸水溶液を調製した。次に、得られたヒアルロン酸水溶液を、単位面積当たりのヒアルロン酸の含有量が7.5mg/cm2となるように底面積が9.1cm2のプラスチックシャーレに入れた後、直径3.4cmのポンチでカットしたそれぞれのフィルム状物(基材)、またはポリ乳酸フィルム(基材)をヒアルロン酸水溶液上にのせ、-82℃の冷凍庫で凍結させた。各基材の用いた他のポリマー及びグリセリンの含有量を表16に示す。次に、圧力10Pa以下においてヒアルロン酸水溶液をシャーレ内で凍結乾燥(24時間)させることにより、凍結乾燥体/基材の2層からなる口腔粘膜貼付材を得た。口腔粘膜貼付材の厚みは、それぞれ約0.75cmであった。次に、実施例1~6と同様にして、各口腔粘膜貼付材の性状、口腔粘膜への貼り付き状況、及び残存状況を評価した。結果を表16に示す。なお、実施例85~実施例87の口腔粘膜貼付材においては、口腔粘膜に対する粘着性の低い基材の上にヒアルロン酸を含む凍結乾燥体が積層された構成を備えているため、口腔粘膜に口腔粘膜貼付材を貼り付ける際に、手が湿っていても基材の凍結乾燥体に貼り付かず、口腔内への適用性に特に優れていた。
2 基材
10 口腔粘膜貼付材
10a 口腔粘膜との接着面
Claims (13)
- 口腔粘膜との接着面に、ポリマーを含む凍結乾燥体を備えた口腔粘膜貼付材であって、
前記凍結乾燥体中の前記ポリマーの含有量が、20質量%以上であり、
前記ポリマー中のヒアルロン酸の含有量が、50質量%以上である、口腔粘膜貼付材。 - 前記ヒアルロン酸の分子量が、1×105ダルトン以上である、請求項1に記載の口腔粘膜貼付材。
- 下記の測定方法によって測定される前記ヒアルロン酸の極限粘度が、3dL/g以上である、請求項1又は2に記載の口腔粘膜貼付材。
(極限粘度の測定法)
ヒアルロン酸50mgを量り、0.2mol/L塩化ナトリウム溶液に溶かして100mLとした液、並びに、この液10mL、15mL、及び20mLを量り、それぞれに0.2mol/L塩化ナトリウム溶液を加えて25mLとした液を、それぞれ試料溶液とする。各試料溶液と0.2mol/L塩化ナトリウム溶液について、日本薬局方 第17局の「一般試験法の2.53 粘度測定法の1. 第1法 毛細管粘度計法」の規定に準じた粘度測定法により30.0±0.1℃の環境で比粘度を測定し、還元粘度を算出する。還元粘度を縦軸に、ヒアルロン酸の濃度(g/100mL)を横軸にとってグラフを描き、各点を結ぶ直線と縦軸との交点から極限粘度を求める。
ただし、比粘度及び還元粘度は次式から求める。
比粘度=(試料溶液の流下秒数÷0.2mol/L塩化ナトリウム溶液の流下秒速)-1
還元粘度=比粘度÷ヒアルロン酸の濃度(g/100mL) - 前記凍結乾燥体に含まれる前記ヒアルロン酸の含有量が、0.1mg/cm2以上である、請求項1~3のいずれかに記載の口腔粘膜貼付材。
- 基材と、この基材の上に積層された前記凍結乾燥体とを備える、請求項1~4のいずれかに記載の口腔粘膜貼付材。
- 前記凍結乾燥体が、前記ヒアルロン酸とは異なるポリマーを0質量%~20質量%含む、請求項1~5のいずれかに記載の口腔粘膜貼付材。
- 前記凍結乾燥体が、ヒアルロン酸とは異なる酸をさらに含んでいる、請求項1~6のいずれかに記載の口腔粘膜貼付材。
- 前記凍結乾燥体が、糖及び多価アルコールの少なくとも一方をさらに含んでいる、請求項1~7のいずれかに記載の口腔粘膜貼付材。
- 口腔粘膜疾患の予防または治療に使用される、請求項1~8のいずれかに記載の口腔粘膜貼付材。
- 前記口腔粘膜疾患が、がん治療に起因する、請求項9に記載の口腔粘膜貼付材。
- 口腔粘膜に適用される減感作療法に使用される、請求項1~8のいずれかに記載の口腔粘膜貼付材。
- 口腔粘膜に適用される経口腔粘膜吸収製剤に使用される、請求項1~8のいずれかに記載の口腔粘膜貼付材。
- 請求項1~12のいずれかに記載の口腔粘膜貼付材の製造方法であって、
ポリマーを含む水溶液を用意する工程と、
前記水溶液を凍結乾燥する工程と、
を備えており、
前記ポリマーとして、ヒアルロン酸が50質量%以上含まれるものを用いる、口腔粘膜貼付材の製造方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17834328.1A EP3492073B1 (en) | 2016-07-27 | 2017-07-25 | Oral mucosa application material and method for producing same |
CN201780039462.6A CN109328058A (zh) | 2016-07-27 | 2017-07-25 | 口腔粘膜贴附材料及其制造方法 |
US16/320,017 US10842741B2 (en) | 2016-07-27 | 2017-07-25 | Oral mucosa application material and method for producing same therefor |
JP2017561002A JP6281968B1 (ja) | 2016-07-27 | 2017-07-25 | 口腔粘膜貼付材及びその製造方法 |
KR1020197002238A KR102426461B1 (ko) | 2016-07-27 | 2017-07-25 | 구강 점막 부착재 및 그의 제조 방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016147076 | 2016-07-27 | ||
JP2016-147076 | 2016-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018021326A1 true WO2018021326A1 (ja) | 2018-02-01 |
Family
ID=61016133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/026898 WO2018021326A1 (ja) | 2016-07-27 | 2017-07-25 | 口腔粘膜貼付材及びその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10842741B2 (ja) |
EP (1) | EP3492073B1 (ja) |
JP (1) | JP6281968B1 (ja) |
KR (1) | KR102426461B1 (ja) |
CN (1) | CN109328058A (ja) |
WO (1) | WO2018021326A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019146777A1 (ja) * | 2018-01-29 | 2019-08-01 | 株式会社リタファーマ | 医薬製剤及びその製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019057035A1 (en) * | 2017-09-19 | 2019-03-28 | The Hong Kong University Of Science And Technology | BIOCOMPATIBLE MATERIAL AND METHODS OF MAKING AND USING THE SAME |
KR102044515B1 (ko) | 2019-08-20 | 2019-11-14 | 이영환 | 구강점막 부착력이 우수한 서방형 구강붕해용 필름 및 이의 제조방법 |
KR20240040272A (ko) * | 2022-09-21 | 2024-03-28 | 동국대학교 산학협력단 | 약물을 담지한 동결건조 히알루론산을 포함하는 점막 투여용 약물 전달체 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5441320A (en) * | 1977-09-08 | 1979-04-02 | Teijin Ltd | Slow release preparation and its manufacturing |
JP2000319167A (ja) * | 1999-05-12 | 2000-11-21 | Nitto Denko Corp | 口腔内貼付シート |
JP2001163745A (ja) * | 1999-12-08 | 2001-06-19 | Lion Corp | 口腔用貼付製剤 |
JP2005263759A (ja) * | 2004-03-22 | 2005-09-29 | Jiyugaoka Clinic | 皮膚浸透性シート |
JP2008295885A (ja) * | 2007-06-01 | 2008-12-11 | Bio Verde:Kk | 2反応剤型の医療用含水ゲル形成剤、及び、これより得られるヒアルロン酸ゲル |
US20090325861A1 (en) * | 2006-08-28 | 2009-12-31 | Rexaderm ,Inc. | Dry wound dressing and drug delivery system |
WO2010013656A1 (ja) * | 2008-07-28 | 2010-02-04 | チッソ株式会社 | 包材 |
JP2012515035A (ja) * | 2009-01-16 | 2012-07-05 | ガイストリヒ・ファーマ・アクチェンゲゼルシャフト | 組織再生のための方法および膜 |
CZ28634U1 (cs) | 2015-05-05 | 2015-09-14 | Contipro Pharma A.S. | Dentální přípravek na bázi hyaluronanu a oktenidin dihydrochloridu |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1251151B (it) | 1991-08-05 | 1995-05-04 | Fidia Spa | Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati |
JP4808294B2 (ja) * | 1999-03-03 | 2011-11-02 | 日東電工株式会社 | 口腔内貼付製剤 |
TWI248820B (en) | 1999-03-03 | 2006-02-11 | Nitto Denko Corp | Oral adhesive sheet and oral adhesive preparation |
IT1318649B1 (it) * | 2000-07-28 | 2003-08-27 | Propharma S R L Ora Sinclair P | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti. |
US20030124178A1 (en) | 2001-12-28 | 2003-07-03 | Haley Jeffrey T. | Soft, adherent, soluble oral patch |
DE102004025495A1 (de) * | 2004-05-21 | 2005-12-15 | Dr. Suwelack Skin & Health Care Ag | Verfahren zur Herstellung von Alginat-haltigen porösen Formkörpern |
KR100885178B1 (ko) * | 2008-03-19 | 2009-02-23 | 고려대학교 산학협력단 | 점착성 약제 조성물 |
US8231493B2 (en) | 2009-07-27 | 2012-07-31 | Eaton Corporation | Differential having improved torque capacity and torque density |
CZ22394U1 (cs) | 2011-03-11 | 2011-06-20 | Contipro C, A.S. | Antimikrobiální smes a kryt pro podporu hojení ran s antimikrobiálním úcinkem |
WO2013110340A1 (en) | 2012-01-27 | 2013-08-01 | Beta Pharma S.A. | Edible slow dissolving film for treating oral ulcerations |
PL2827914T3 (pl) * | 2012-03-22 | 2019-09-30 | Trb Chemedica International S.A. | Sposób naprawy więzadła lub ścięgna |
US20160022644A1 (en) | 2014-07-22 | 2016-01-28 | Tsu-I Catherine Wang | Oral Transmucosal Compositions Including Aromatase Inhibitors for Treating Female Infertility |
CN108079372A (zh) * | 2015-06-24 | 2018-05-29 | 安溪县海宏生物科技有限公司 | 一种真皮组织修复材料的制备方法 |
-
2017
- 2017-07-25 JP JP2017561002A patent/JP6281968B1/ja active Active
- 2017-07-25 WO PCT/JP2017/026898 patent/WO2018021326A1/ja unknown
- 2017-07-25 KR KR1020197002238A patent/KR102426461B1/ko active IP Right Grant
- 2017-07-25 CN CN201780039462.6A patent/CN109328058A/zh active Pending
- 2017-07-25 EP EP17834328.1A patent/EP3492073B1/en not_active Revoked
- 2017-07-25 US US16/320,017 patent/US10842741B2/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5441320A (en) * | 1977-09-08 | 1979-04-02 | Teijin Ltd | Slow release preparation and its manufacturing |
JP2000319167A (ja) * | 1999-05-12 | 2000-11-21 | Nitto Denko Corp | 口腔内貼付シート |
JP2001163745A (ja) * | 1999-12-08 | 2001-06-19 | Lion Corp | 口腔用貼付製剤 |
JP2005263759A (ja) * | 2004-03-22 | 2005-09-29 | Jiyugaoka Clinic | 皮膚浸透性シート |
US20090325861A1 (en) * | 2006-08-28 | 2009-12-31 | Rexaderm ,Inc. | Dry wound dressing and drug delivery system |
JP2008295885A (ja) * | 2007-06-01 | 2008-12-11 | Bio Verde:Kk | 2反応剤型の医療用含水ゲル形成剤、及び、これより得られるヒアルロン酸ゲル |
WO2010013656A1 (ja) * | 2008-07-28 | 2010-02-04 | チッソ株式会社 | 包材 |
JP2012515035A (ja) * | 2009-01-16 | 2012-07-05 | ガイストリヒ・ファーマ・アクチェンゲゼルシャフト | 組織再生のための方法および膜 |
CZ28634U1 (cs) | 2015-05-05 | 2015-09-14 | Contipro Pharma A.S. | Dentální přípravek na bázi hyaluronanu a oktenidin dihydrochloridu |
DE202016102375U1 (de) | 2015-05-05 | 2016-05-24 | Contipro Pharma A.S. | Dentales Mittel auf Basis von Hyaluronan und Octenidindihydrochlorid |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019146777A1 (ja) * | 2018-01-29 | 2019-08-01 | 株式会社リタファーマ | 医薬製剤及びその製造方法 |
JP6592791B1 (ja) * | 2018-01-29 | 2019-10-23 | 株式会社リタファーマ | 医薬製剤及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109328058A (zh) | 2019-02-12 |
KR20190032384A (ko) | 2019-03-27 |
EP3492073A1 (en) | 2019-06-05 |
KR102426461B1 (ko) | 2022-07-29 |
EP3492073A4 (en) | 2020-03-25 |
EP3492073B1 (en) | 2022-04-27 |
JP6281968B1 (ja) | 2018-02-21 |
US20190262259A1 (en) | 2019-08-29 |
US10842741B2 (en) | 2020-11-24 |
JPWO2018021326A1 (ja) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6281968B1 (ja) | 口腔粘膜貼付材及びその製造方法 | |
KR100912850B1 (ko) | 니코틴 함유 필름 제제 | |
JP3730081B2 (ja) | フィルム状トローチ | |
Mizrahi et al. | Mucoadhesive polymers for delivery of drugs to the oral cavity | |
ES2294180T3 (es) | Composiciones de beta-glucano de cereales, metodos de preparacion y usos de las mismas. | |
JP6519930B2 (ja) | 水溶性ヒアルロン酸ゲル及びその製造方法 | |
CA2674116A1 (en) | Solid film, rapidly dissolvable in liquids | |
Smart | Recent developments in the use of bioadhesive systems for delivery of drugs to the oral cavity | |
US20090053309A1 (en) | Adhesive compositions for the treatment of xerostomia | |
CN110302144B (zh) | 一种缓释型双层口腔溃疡膜及其制备方法 | |
Chaudhari et al. | MUCOADHESIVE BUCCAL DRUG DELIVERY SYSTEM: A REVIEW. | |
US9688779B2 (en) | Treating mucosal lesions with hyaluronan delivered from an adhering troche | |
WO2005084703A1 (ja) | 徐放性の口腔用組成物 | |
CA2950495A1 (en) | Orodispersible film | |
US20150290173A1 (en) | Treatment of skin or mucosal pathology | |
JPWO2017126143A1 (ja) | 水溶性ヒアルロン酸ゲル及びその製造方法 | |
WO2019146777A1 (ja) | 医薬製剤及びその製造方法 | |
CN113713113B (zh) | 一种治疗口腔黏膜疾病的组合物及其制备方法 | |
RU2635769C1 (ru) | Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения | |
JP6806388B1 (ja) | 口腔内粘膜被覆用抗炎症性液状組成物、およびこれを用いた口内炎の予防および/または治療用医薬組成物 | |
Patel et al. | A NOVEL APPROACH FOR BUCCAL DRUG DELIVERY SYSTEM-BUCCAL FILM. | |
Singh et al. | A Comprehensive Review on Buccal DrugDelivery System | |
JP2013006824A (ja) | 可食性組成物、ゼリー状製剤及びゼリー状製剤の製造方法 | |
Bhatt et al. | A review on buccal mucosal route of drug administration | |
Reddy et al. | MUCOADHESIVE BUCCAL DELIVERY OF DRUGS-CHALLENGES AND PRESENT ASPECTS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2017561002 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17834328 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20197002238 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017834328 Country of ref document: EP Effective date: 20190227 |